The import of tetracyclines to the US is forecasted to decrease steadily from 2024 to 2028. In 2023, this value stood at approximately 60 million US Dollars. From 2024 to 2025, there will be a year-on-year decline of about 3.8%. Subsequent years follow a similar downward trend with yearly decreases of about 3.9% through 2028. The compound annual growth rate (CAGR) for the period from 2024 to 2028 indicates an average annual decline. These insights suggest a consistent reduction in imports over the five-year forecast period.

Future trends to watch for include:

Shifts in global supply chain dynamics affecting pharmaceutical imports.
Regulatory changes and impacts on US drug importation policies.
Potential emergence of alternative antibiotics possibly reducing tetracycline demand.